Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Cash from Financing Activities: 2023-2025

Historic Cash from Financing Activities for Contineum Therapeutics (CTNM) over the last 3 years, with Sep 2025 value amounting to $19.1 million.

  • Contineum Therapeutics' Cash from Financing Activities rose 146861.54% to $19.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.9 million, marking a year-over-year decrease of 81.62%. This contributed to the annual value of $109.0 million for FY2024, which is 94.03% up from last year.
  • According to the latest figures from Q3 2025, Contineum Therapeutics' Cash from Financing Activities is $19.1 million, which was up 20,894.51% from $91,000 recorded in Q2 2025.
  • In the past 5 years, Contineum Therapeutics' Cash from Financing Activities registered a high of $108.4 million during Q2 2024, and its lowest value of -$617,000 during Q1 2023.
  • In the last 3 years, Contineum Therapeutics' Cash from Financing Activities had a median value of $91,000 in 2025 and averaged $16.8 million.
  • Over the last 5 years, Contineum Therapeutics' Cash from Financing Activities had its largest YoY gain of 146,861.54% in 2025, and its largest YoY loss of 99.92% in 2025.
  • Over the past 3 years, Contineum Therapeutics' Cash from Financing Activities (Quarterly) stood at -$321,000 in 2023, then skyrocketed by 300.00% to $642,000 in 2024, then soared by 146,861.54% to $19.1 million in 2025.
  • Its Cash from Financing Activities stands at $19.1 million for Q3 2025, versus $91,000 for Q2 2025 and $24,000 for Q1 2025.